ESTEVE Expands U.S. CDMO Capabilities Through Acquisition of Regis Technologies
Through this acquisition, ESTEVE will expand its contract development and manufacturing services for small-molecule APIs from pre-clinical through to commercial manufacturing within the U.S.
International specialty pharmaceutical company, ESTEVE, has announced, in a July 31, 2025 press release, its acquisition of U.S.-based CDMO, Regis Technologies. With this strategic move, ESTEVE CDMO (actively operating under the Esteve Química brand) will gain a physical presence in the U.S.
Specializing in high-quality, small-molecule APIs and pharmaceutical intermediates, ESTEVE CDMO (Esteve Química) provides services, such as spray drying and high-potency API manufacturing for third parties. In addition to the recently acquired U.S. capacity, the outsourcing business also has production plants in Spain, Mexico, and China.
“We are proud to announce that we are increasing our team, and our CDMO solutions for pharmaceutical innovators: this acquisition is adding capabilities, as well as development and manufacturing capacity, while increasing the team of ESTEVE's CDMO business with around 70 skilled people,” said Joan Petit, Chief Industrial Operations Officer of ESTEVE and General Manager of ESTEVE CDMO (Esteve Química), in a company press release (1).
“[The] United States is a strategic market for ESTEVE. This acquisition is a step forward towards our purpose of improving people's lives by increasing our CDMO capabilities and capacity in this market and expanding our integrated services offering,” added Staffan Schüberg, CEO of ESTEVE, in the press release (1).
Founded in 1956, Regis Technologies has provided services, such as process R&D, analytical and stability, current good manufacturing practice (CGMP) API manufacturing, chemistry, manufacturing, and controls support, and a variety of chromatography products, to pharma and biotech companies out of its Chicago, Illinois, base. The company became fully GMP compliant in 1993 and have undergone expansions to advance its capabilities over the years.
“We are happy to join a company that shares our same values, a company that is also family-owned, with more than 90 years of experience, that is committed to people and focused on delivering long-term value to customers,” added Scott Aladeen, President and CEO of Regis Technologies, in the press release (1).
In May 2025, ESTEVE announced it had experienced 5% growth in net revenue for 2024 when compared with 2023, reaching a value of EUR 744 million (2). While maintaining stable net revenues, the CDMO business of ESTEVE contributed positively to the growth by improving the company’s value-added product mix.
“Last year's results are not only a consolidation of the growth trajectory that we have been building in the past four years but also reflect our commitment to improve the quality of life of people through highly specialized solutions,” specified Schüberg in a press release about the company’s annual results report (2). “We are hopeful about the opportunities that lie ahead for ESTEVE and trust that 2025 will be a pivotal year in our advancement as a leading international pharmaceutical company in the field of specialized medicine.”
References
ESTEVE. ESTEVE Acquires Regis Technologies, Expanding U.S. Presence and Capabilities. Press Release, July 31, 2025.
ESTEVE. ESTEVE Increases Net Revenue by 5% and Reaffirms Strategy Towards Becoming a Highly Specialized Company. Press Release, May 14, 2025.